Cytokinetics Inc (CYTK)
Return on equity (ROE)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -526,292 | -526,773 | -539,661 | -430,844 | -389,000 | -282,145 | -215,921 | -257,655 | -215,314 | -228,674 | -155,763 | -134,989 | -127,290 | -114,000 | -140,398 | -131,731 | -121,692 | -117,520 | -109,964 | -105,374 |
| Total stockholders’ equity | US$ in thousands | -386,323 | -438,801 | -333,115 | -229,020 | -107,900 | -15,977 | 111,414 | 116,261 | 243,863 | 249,020 | 16,489 | 67,846 | 113,383 | 149,605 | -78,080 | -45,711 | -10,937 | -19,869 | -4,896 | 3,372 |
| ROE | — | — | — | — | — | — | -193.80% | -221.62% | -88.29% | -91.83% | -944.65% | -198.96% | -112.27% | -76.20% | — | — | — | — | — | -3,124.97% |
December 31, 2023 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-526,292K ÷ $-386,323K
= —
Based on the data provided, Cytokinetics Inc's return on equity (ROE) for the first two quarters of 2022 was negative, with a particularly significant decrease from Q3 2022 to Q1 2022. The negative ROE values indicate that the company's net income was insufficient to cover its shareholders' equity during these periods.
The drastic drop in ROE from Q3 2022 to Q1 2022 suggests that the company faced challenges or incurred losses that impacted its profitability and shareholder value. It is essential for investors and stakeholders to closely monitor Cytokinetics Inc's financial performance and assess the company's strategies to improve its ROE and overall profitability in the future.
Peer comparison
Dec 31, 2023